We are thrilled to announce that NNE has been honoured as a Børsen Gazelle Company 2024.

NNE had another impressive financial year in 2023. We delivered a historically high revenue of DKK 2,781 million, corresponding to an increase of 46% compared to 2022.  

Novo Nordisk today announced plans to invest more than DKK 42 bn starting in 2023 to expand existing manufacturing facilities in Kalundborg, Denmark. NNE has been assigned the engineering task as Novo Nordisk’s partner from design to construction.

2021 was a strong financial year for NNE, growing our turnover with 36%. Watch the video for highlights or read the report in full.

With NNE as its engineering partner from design to construction, Novo Nordisk is erecting three new facilties and expanding an existing one to increase API capacity.

"I thank PDA and feel humble and proud to receive this Service Appreciation Award for my involvement in the PDA Pharmacopedial Interest Group."

Our 2020 annual report is out, showing strong financial results for NNE. Watch the video for highlights or read the report in full.

Meet our new CFO, Sofie Mørck Jarl and find out what she is looking forward to in her new role.

Unibio and NNE have entered into a strong digital partnership. The unique cooperation  will benefit both Danish companies and the entire biotech industry.

NNE emerges from 2019 with a solid result and a focused business - ready to drive digitalization and green initiatives in Danish pharmaceutical production.

Read about the new strategic partnership between NNE and Bigfinite which aims to help pharma manufacturers towards Pharma 4.0.

With a turnover of DKK 2.2 billion, an operating profit of DKK 136 million and an operating profit margin of 6%, the international pharma engineering company came out of 2017 with a satisfactory result.

Today, NNE announced the appointment of Gary Lohr as its new Corporate Vice President and General Manager for NNE in the US. Lohr will take up the position as of January 1, 2018.

With a turnover of DKK 2.4 billion, an operating profit of DKK 203 million and an operating profit margin of 8.4%, the international pharma engineering company came out of 2016 with a very strong performance, also in the international subsidiaries.

With a turnover of DKK 2.4 billion, an operating profit of DKK 203 million and an operating profit margin of 8.4%, the international pharma engineering company came out of 2016 with a very strong performance, also in the international subsidiaries.

Pharma and biotech manufacturers benefit from best-in-class pharma MES combined with local implementation support from PAS-X Endorsed Service Partner.

2015 was the best year to date for the engineering consultancy company NNE Pharmaplan. 

NNE Pharmaplan will integrate the latest technology to ensure agile operations for Novo Nordisk at their new insulin filling facility in Hillerød, Denmark.

Jesper Kløve from Novo Nordisk succeeds Morten Nielsen as CEO in the pharma engineering company NNE Pharmaplan. The change is a consequence of Novo Nordisk’s planned investment in a new diabetes API plant in USA.